The developer expects demand from workers at large corporate campuses nearby, including those for Eli Lilly and Co., Indiana Farm Bureau and Anthem Inc.
Joshua Smiley, who was Lilly’s second-highest-paid employee, was named CFO in January 2018. Lilly said Smiley also engaged in “inappropriate personal communications” with other employees.
Lilly has spent three decades and more than $3 billion trying to find a way to treat Alzheimer’s disease. Its latest drug, donanemab, finally shows real promise.
Woodard talked to host Mason King about his adventure restoring the Stutz Business and Arts Center, about his decision to sell a majority share in the complex and what the new owners have in store for the buildings.
The antibody treatment bamlanivimab was Lilly’s second-highest selling product in the final quarter of 2020, trailing only the popular diabetes drug Trulicity.
The new majority owner says it plans to retain the Stutz property’s historic character but isn’t yet revealing details about its plans for the 110-year-old downtown complex.
The maker of animal feeds and vaccines also is closing research and development sites in Germany and New Zealand, and making smaller cuts elsewhere. Altogether, Elanco is chopping 350 jobs in 23 countries.
Lilly’s announcement Thursday comes as the disease continues to hit hard in U.S. nursing homes, accounting for more than 100,000 deaths of residents and staff over the course of the pandemic.
Merus N.V. specializes is so-called CD3 engaging T-cell therapies, a growing area of cancer research, based on immunotherapy, or using the immune system’s T cells to find and shrink tumors
The bill would shield businesses and individuals from coronavirus civil liability lawsuits unless there was gross negligence or willful or wanton misconduct that could be proven with “clear and convincing evidence.”
So far this month, drugmakers have hiked prices on 636 drugs, according to research by GoodRx, which tracks prescription drug prices and offer a mobile app to help consumers find the lowest prices on hundreds of drugs.
The experimental drug, donanemab, could be a huge breakthrough for Lilly, which has spent billions of dollars over 30 years researching treatments for Alzheimer’s disease, only to see them fall short in clinical trials.
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
The biggest chunk—$10.5 million—has been dedicated to 15 community and multi-service centers that offer a range of services, such as health care, child care, counseling, job training and youth development, as well as programs for seniors.
